Driving the Next Generation of Cell-Based Therapies

MaxCyte Q2 2021 Business Update and Recent Highlights

NASDAQ: MXCT

LSE: MXCT, MXCN

October 2021

Disclaimer

The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individual or organization to a significant risk of losing all of their investment. If you are in any doubt about the investment to which this Presentation relates, you should consult a person authorized by the Financial Conduct Authority who specializes in advising on securities of the kind described in this Presentation or your stockbroker, bank manager, solicitor, accountant or other financial adviser. This Presentation has been issued by MaxCyte Inc (the “Company”) a Company trading on AIM, a market operated by the London Stock Exchange. This does not constitute or form of, not be construed as an offer or invitation to sell or issue or any solicitation of, any offer to purchase or subscribe for any securities in the Company in any jurisdiction. Neither the Presentation, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in any connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any such securities. This Presentation does not constitute a recommendation regarding the securities of the Company.

This presentation is only addressed to and directed at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (iii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and/or (iv) any other persons to whom this presentation may otherwise lawfully be communicated without contravention of section 21 of the Financial Services and Markets Act 2000 or to whom it may otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"). This presentation may not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this presentation relates is available only to relevant persons

Certain statements in this Presentation are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "expect", "envisage", "estimate", "intend", "may", "plan", "potentially", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward looking statements, many of which are beyond the control of the Company. In particular, the outcome of clinical trials (including, but not limited to the Company's CARMA trial) may not be favorable or potential milestone payments associated with the Company's licensed programs may not be received. In addition, other factors which could cause actual results to differ materially include risks associated with vulnerability to general economic and business conditions, competition, regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

No statement in the presentation is intended to be, or intended to be construed as, a profit forecast or profit estimate or to be interpreted to mean that earnings per Company share for the current or future financial years will necessarily match or exceed the historical earnings per Company share. As a result, no undue reliance should be placed on such statements.

A Leading Provider of Cell-engineering Platform

With 400+ platforms in place, our proprietary technology platform unlocks the significant potential of advanced therapeutics

- Enables delivery of almost any molecule into almost any cell type
- Leads the industry in performance (measured by consistency, efficiency, viability, flexibility and scale)
- Extensive product portfolio, supported by a robust intellectual property portfolio
- ~23% 5-year CAGR of organic revenue growth; pharmaceutical-level gross margins of ~89%

Leading the growing next-generation cell therapy market and capitalize on rising demand for non-viral engineering approaches

- 20+ years of cell engineering expertise; 20+ field sales and application scientists that support our customers
- Significant number of collaborations with industry and academia
- Supported by our FDA Master File and International Technical Files to reduce clinical risk/shorten clinical development
- Used to manufacture drug products for over 35 clinical trials to date

Innovative business model focused on value creation and shared partnership success

- Allows MaxCyte to participate in the value created by our partners' programs
- 14 Strategic Platform Licenses (SPLs), which include over $950m in potential pre-commercial milestone payments with upside from commercial sales-based payments
- Focused over the long-term on creating a diverse portfolio of patient treatments for indications developed by our strategic partners

We Are Just Beginning Our Forward Momentum

Impact

1999 Scientific Foundation

2000 MaxCyte Scalable GT Transfection System

2002 FDA Master File

2005 VLX Large-Scale Transfection System (prototype)

2008 MaxCyte Scalable STX Transfection System

Listing

London Stock Exchange/AIM

LSE: MXCT, MXCN
March 2016

2016 London Stock Exchange | AIM

2018 MaxCyte ATX Gen 2 Transfection System

2019 MaxCyte ExPERT™ Platform

Listing

Nasdaq: MXCT

July 2021

2021 Nasdaq

MaxCyte®

14 Strategic Platform Licenses signed since 2017

65 FTEs (19 w/ PhD degrees)*

20+ field sales and application scientists*

*As of March 31, 2021

Cell Therapy

Drug Discovery

MaxCyte®

MaxCyte: Leading Partner for Complex Cellular Engineering

50+
Potential SPLs
Current addressable market*

14
SPLs signed since 2017

75+
Programs
Clinical Licenses that are part of our SPLs

>15%
are in the clinic*

**IND clearance or later*

Note: * Number of gene-modified cell therapy companies across immuno-oncology and inherited disorders using non-viral delivery in preclinical development.

Updated as of July 30, 2021

14 **Strategic Platform Licenses (SPLs), including 3 signed in 2021**

Allogene Therapeutics
APEIRON BIOLOGICS
Beam Therapeutics
CARIBOU BIOSCIENCES
CASEBIA THERAPEUTICS
celularity
Sana Biotechnology
CRISPR Therapeutics
editas MEDICINE
Kite A GILEAD Company
KSQ
MYELOID Therapeutics, Inc.
PRECISION BIOSCIENCES
VOR BIOPHARMA

Value Creation from SPLs

- Licensing deals include significant development milestones and high-value participation in future commercial success of partners

Potential value of pre-commercial (clinical development) milestones from SPLs exceeds $950m USD*

Sales-based payments upon partner's product commercialization

Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success

Milestone revenue is MaxCyte's highest growth revenue stream



MaxCyte®

**As of January 20, 2021*

Note: Graph is for illustrative purpose

Continued Investment in Cell Therapy

1,800+

Cell and gene therapies in development globally

Source: ASGCT – Pharma Intelligence

~700

Genetically-modified cell therapies in development

Source: Evaluate Pharma

40+

Allogeneic companies with assets in development

Source: William Blair Research

Total amount of 2020 global financings for cell and gene therapy companies

$19.9B

Source: Alliance for Regenerative Medicine

Projected sales of gene-modified cell therapies by 2026



Source: Evaluate Pharma

First next-generation engineered cell therapy expected to be approved in

2023 - 2024

Source: Evaluate Pharma

ExPERT™ Platform Addresses Industry Challenges

Challenge	MaxCyte's Solutions
Development times and cost of viral vectors as delivery method has increased	Non-viral approaches address viral vector capacity constraints and safety concerns
Next-generation cell therapy programs have become increasingly complex	Flow Electroporation® technology facilitates multiplex engineering; challenging with viruses given payload limitations, capacity constraints, and cost
Regulatory risk increases with new unknowns (donor cells, 2nd/3rd/4th gen approaches, new indications)	FDA Master File can be appended to regulatory filings to reduce regulatory risk
Vein-to-vein manufacturing times are high; efficiencies needed to deliver medicines to patients faster	ExPERT™ platform provides industry leading efficiency/viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production

MaxCyte®

The ExPERT™ Platform Enabling Non-viral Cell Engineering

- Launched in 2019 based on MaxCyte's **proprietary Flow Electroporation® technology** that is continuing to be optimized for the past 20+ years
- Leverages the reversible permeability of the cell membrane in response to an electric charge
- **Universally delivers molecules,** such as nucleic acids and proteins, to cells
- **Agnostic to cell type, approach (auto/allo)** and/or gene manipulation technology
- Enables customers to use a **single platform from concept through to the clinic** in a GMP environment
- Supported by a **robust intellectual property portfolio** (50+ patents in US and foreign jurisdictions and 75+ patents pending)

ExPERT™ Instrument Portfolio

Small to mid-scale RUO | Full scale RUO | Full scale GMP

High Performance
- >90% transfection efficiencies (depending on cell type and molecule)
- >90% cell viabilities
- Computer-controlled system for reproducible results

Flexibility
- Single, fully-defined, animal component-free electroporation buffer for all cell types
- Pre-loaded library of validated, cell-specific products

Scalability – ability to transfect:
- 75,000 to 7 million cells in seconds
- Up to 20 billion cells in less than 30 minutes
- And up to 200 billion cells in less than 30 minutes with the high scale VLX

High Quality
- Sterile, single-use processing assemblies (PAs) – "disposables"
- Closed, cGMP-compliant, ISO-certified, and CE marked instruments
- Supported by US FDA Master File and global equivalents

Growing Opportunity from R&D to Therapeutics

DRUG DISCOVERY & DEVELOPMENT - CELLS TO DISCOVER DRUGS

Blue-chip client base includes the top ten global pharma companies and 20 of the top 25*

MaxCyte Revenue Model

Instrument sale**

+

Single-use disposables (processing assemblies)

=

Razor/razor blade economics

STx ATx

CELL THERAPY - CELLS AS DRUGS

14 SPLs with cell therapy developers that allow for more than 75 clinical programs; > $950m in potential pre-commercial milestones

GTx

MaxCyte Revenue Model

Annual instrument license fee***

+

Single-use disposables (processing assemblies)

+

Strategic partnership terms

=

Razor/razor blade economics and share of therapeutic economics

** Based on 2020 revenue*
*** Includes RUO- non-exclusive license only; $119,000 list price for STx sale*

**** $150,000 per year lease price for pre-clinical use or $250,000 per year lease price for clinical use*

Example: Typical Single-product Revenues from Representative License Deal



Cell Therapy Partner Program Value Schematic

- Instruments and Processing Assemblies
- Milestones
- Sales-based Payments

MaxCyte®

Building a Large Portfolio of Diverse Customers

MaxCyte's clinical customer base reflects the industry in diversity of cell types, sources, and indications

Cell Type/Approach



CAR-T
TCR
CAR-NK / NK
Stem Cell
Other

Cell Source



Auto
Allo

Indications



MM
AML / ALL
Other Heme Malig.
Pancreatic
Lung
Ovarian
Other Solid Tumors
Genetic Disorders
NHL
Other

Note: * All clinical gene-modified cell therapies across therapeutic areas (e.g., oncology, inherited disorders, immune disorders) utilizing viral and/or non-viral delivery are included, while other regenerative medicine programs that do not entail genetic modification to obtain a cell-based therapeutic product (e.g., tissue engineering, immune or stem-cell therapies that are not genetically modified) are excluded.

Q2 Financials Update

Q2 Key Financial Highlights

Revenues ($M)



Operating Expenses ($M)



The overall increase in operating expense was driven by increased headcount and higher stock-based compensation (principally due to stock-price appreciation) and increase in legal and professional service expenses.

Balance Sheet

Total cash, including cash equivalents, was $73.4 million as of June 30, 2021 excluding the $201.8 million in gross proceeds from the Company's August, 2021 U.S. public listing.

MaxCyte®

1H 2021 Summary and Outlook for 2021+

1H 2021 Achievements & Recent Highlights

- Generated total revenue of $13.6 million in the first half of 2021, representing 25% growth with the same period in 2020
- Signed 3 SPL agreements year to date (Myeloid Therapeutics, Celularity, and Sana Biotechnology)
- Expanded Board of Directors with the appointment of Ms. Rekha Hemrajani and Dr. Yasir Al-Wakeel
- Completed U.S. initial public offering on Nasdaq Global Select Stock Market, raising $201.8 million in gross proceeds

2021+ Goals

1. Strong top-line growth driven by cell therapy
2. Invest in manufacturing expansion/automation
3. Continue to launch new products to address customer needs and expand into new applications
4. Working towards commercializing the large-scale platform (VLx) and associated consumables under the ExPERT™ brand
5. Future investments in upstream and downstream technologies in cell therapy through partnerships or acquisitions

MaxCyte®

Thank You

ir@maxcyte.com

www.MaxCyte.com